
Apyx Medical Inc
Health Care · USD
Price
$3.96
Cap
$166M
Earnings
3/3 beat
30d Trend
-1%
Near 52-week highs — limited upside before resistance
Target range: $6 – $8 (consensus: $6.5)
Consensus: Moderate Buy
Earnings history
Q4 2025
BEAT
-0.03 vs -0.06
Q3 2025
BEAT
-0.03 vs -0.05
Q2 2025
BEAT
-0.03 vs -0.21
Key macro factors
Regulatory Landscape and FDA Scrutiny: Apyx Medical faces regulatory issues, including the lingering impact of an FDA warning letter, which could affect product approvals and operational stability.
Competition and Evolving Aesthetics Market: The surgical aesthetics market is experiencing increased competition and changing dynamics, notably the rise of GLP-1 treatments, which may influence demand for traditional aesthetic procedures.
Global Economic Conditions and Consumer Discretionary Spending: As demand for Apyx Medical's surgical aesthetics products is tied to consumer discretionary spending, broader global economic challenges addressed by organizations like the IMF and World Bank could impact consumer confidence and willingness to invest in elective cosmetic procedures.
Apyx Medical Corporation is an advanced energy technology medical device company focused on surgical aesthetics, developing, manufacturing, and marketing products like Renuvion and the AYON Body Contouring System for cosmetic surgery and J-Plasma for hospital surgical markets.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.
